SLC5A2 and diabetes mellitus: The hypothesis that SGLT2 inhibitors confer renal protection was tested in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, which reported a 30% reduction in the primary composite endpoint (end-stage kidney disease, doubling of the serum creatinine level or death from renal or cardiovascular causes) [3].